News – Page 1081 – Endpoints News

After building a rep as an architect of experiments, RxCelerate plants its flag in America

8 years ago

Synthetic biology pioneer Synthorx recruits Cleave's Laura Shawver for top position

8 years ago

How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash

8 years ago

Roiled by financial turmoil, Teva's CEO boots R&D chief, top execs in C-suite overhaul

8 years ago

Intrexon taps new COO, CBO in executive reshuffle; Denali targets up to $182M in IPO

8 years ago

Biogen’s answer to Alkermes’ Tecfidera threat? Buy it, but don’t spend too much

8 years ago

Catalyst heads back to the FDA in search of an elusive OK after Firdapse scores high in new PhIII

8 years ago

AstraZeneca teams with China-owned fund to launch a new biopharma drug development company

8 years ago

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

8 years ago

Flagship, Arch cut their losses, quietly shutter Ensemble Therapeutics as pipeline plans fizzle out

8 years ago

Merck blueprints $1.3B research hub in a post-Brexit London, with 950 staffers

8 years ago

Teva R&D chief out as new CEO picks up the ax and aims at deep cuts to rescue a faltering biopharma — report

8 years ago

The 10 most popular stories in Endpoints News — so far in 2017

8 years ago

Innate shares crushed on second big setback for Bristol-Myers partnered lirilumab

8 years ago

Open plan designs: The good, the bad and the ugly; Fresenius adding 400-plus staffers

8 years ago

Under pressure from copycats, Roche sues Pfizer over Herceptin rival

8 years ago

Study replicates pivotal trial results using 'real world evidence'

8 years ago

#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL

8 years ago

Six top biotech VCs take a look at the latest trends, and offer their thoughts on 2018

8 years ago

With billions riding on their success, GSK bags quick OK for its two-drug HIV combo Juluca

8 years ago

Jeff Capello joins Biogen as CFO; Tesaro enters $500M loan agreement; Palatin licenses female libido drug to Korea's ...

8 years ago

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

8 years ago

French upstart Step Pharma raises €8.6M, taking immunosuppressive drugs to the clinic

8 years ago

Cytokinetics axes lead drug after it implodes in a PhIII muscle trial for ALS, shares crater

8 years ago

First page Previous page 1078 1079 108010811082 1083 1084 Next page Last page